The Global Market for Biomarkers, 2015-2020 (Cancer Markers, Cardiac Markers, Immunological Disease Markers, Infectious Disease Markers, Others)

   Single User - $1,995
   Site License (one location, 10 users) - $2,995
   Corporate License - $3,990

Published Dec 10, 2015 | 683 Pages | Pub ID: KLI5789361

The Global Market for Biomarkers (Cancer Biomarkers, Cardiovascular Disease Biomarkers, Immunological Disease Biomarkers, Infectious Disease Biomarkers, Neurological Disease Biomarkers, Novel Biomarkers for Other Diseases)

Biomarkers are biological or biochemical molecules, genetic changes, or other characteristics that can be measured, and that indicate or predict a condition, risk, or likely response. Biomarkers can be used for a range of diagnostic applications including predicting disease risk, diagnosis, predicting prognosis, identifying appropriate therapy for an individual, monitoring disease or for return of a disease, and other applications. Biomarkers also have important roles in drug discovery and development. The Global Market for Biomarkers analyzes the current and future markets for biomarkers.

Segmentation of Individual Biomarker and Relevant Category Markets

Market analyses in this report cover world markets for biomarker diagnostic markets.  Biomarker markets are broken out to individual markers where possible, and in category market segments where tests are bundled.  The report includes the following segmentation:
  • Worldwide Diagnostic Biomarker Market by Disease Indication – 2015 and 2020 (Cancer, Cardiovascular disease, Autoimmune disease and allergy, Infectious disease, Other disease applications, Total)
  • Worldwide Cancer Biomarkers Diagnostic Market – 2015 and 2020 (IHC, ISH, PSA, CEA, CA 125, AFP, Other Immunoassays - Tumor Markers, Flow Cytometry, Fecal occult blood, Rapid Tests – PSA, NMP22, EGFR/HER2 Segment, Total)
  • Worldwide Cardiac Marker Diagnostic Market – 2015 and 2020 (Acute Condition Cardiac Marker Segment: CK-MB, troponin I, troponin T, myoglobin, brain natriuretic peptide [BNP]; Other Cardiac Marker Segment: proBNP, hsCRP, homocysteine, others; Cholesterol/Lipids; Coagulation: PT/INR - lab, D-dimer, Molecular [Thrombophilia SNPs], POC Cardiac Marker Segment; Total)
  • Worldwide Autoimmune Disease and Allergy Biomarkers Diagnostic Market – 2015 and 2020
  • Worldwide Infectious Disease Biomarkers Diagnostic Market – 2015 and 2020 (Laboratory immunoassays: Hepatitis, HIV, STDs, TORCH, Respiratory, Sepsis, Parasitology, Mycology, Others; Rapid immunoassays: Influenza, HIV, Malaria, Hepatitis, STDs, C. difficile, E. coli, Strep A, H. pylori, Others; Molecular assays: Healthcare-Acquired Infections [HAIs], HIV, Hepatitis, Chlamydia/Gonorrhea [CT/NG], HPV, Respiratory, Mycobacteria/TB, Other; Total)
  • Worldwide Diagnostic Market for Selected Other Biomarkers – 2015 and 2020 (General Clinical Chemistry, Fertility/Pregnancy, Thyroid, Diabetes/HbA1c, Chromosome Analysis and Inherited Disease, Cystic Fibrosis, Other, Total)
  • Worldwide Biomarker Market - Diagnostic versus Research Applications – 2015 and 2020
  • Worldwide Biomarker Market by Geography – 2015 and 2020 (North America, European Union, Japan, ROW, Total)
  • The world markets for biomarkers and biomarker tests are provided in U.S. dollars for 2015 and 2020. The worldwide market for biomarkers by disease indication is provided, including the market for tests for biomarkers (diagnostics products) sold to clinical laboratories, and also products sold to researchers.
In addition, The Global Market for Biomarkers includes financial information on deals involving biomarker companies. In the table summarizing these deals, for companies that reported this information in currencies other than U.S. dollars, both the actual reported financial information and an estimated value in U.S. dollars at the time of the agreement are provided.

The biomarker market is large, reflecting the large market for diagnostic tests based on these biomarkers, and also the ongoing efforts to discovery, validate, and commercialize new biomarkers. Growth in this market is fueled by factors that are fostering the growth of both the research and the diagnostics market. Market drivers and challenges are discussed in the report.

Over 100 Companies Profiled

The large and growing biomarker market has attracted a lot of attention, and companies entering the market. Thus this has become a highly competitive market. The report profiles companies involved in the biomarkers market, including:
  • 14M Genomics Ltd.
  • 20/20 GeneSystems, Inc.
  • 23andMe, Inc.
  • A&G Pharmaceutical, Inc.
  • Abacus Diagnostica Oy
  • Abbott Laboratories
  • Abcodia Ltd.
  • Accelerate Diagnostics, Inc.
  • Acobiom
  • ACT Genomics Co., Ltd.
  • Acumen Pharmaceuticals, Inc.
  • Adaptive Biotechnologies Corporation
  • Adlyfe Inc.
  • Admera Health (A GENEWIZ Company)
  • Affymetrix, Inc.
  • Agena Bioscience Inc.
  • Agendia NV
  • Agilent Technologies Inc.
  • Alere Inc.
  • Almac Group Limited
  • Amarantus BioScience Holdings, Inc.
  • Ambry Genetics Corp.
  • Aperiomics, Inc.
  • ApoCell, Inc.
  • Applied Proteomics, Inc.
  • Associates of Cape Cod, Inc. (ACC)
  • Asuragen, Inc.
  • AsymmetRx Medical, Inc.
  • Athena Diagnostics, Inc. (A Quest Diagnostics Business)
  • Atlas Genetics Ltd.
  • Atossa Genetics Inc.
  • Augurex Life Sciences Corp.
  • Augurix SA/Augurix Diagnostics
  • Avant Diagnostics, Inc. (Formerly Arrayit Diagnostics Inc.)
  • Axela, Inc.
  • Axis-Shield Diagnostics, Ltd. (An Alere Company)
  • AXO Science
  • Banyan Biomarkers, Inc.
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company (BD)
  • BG Medicine, Inc.
  • The Binding Site Group Ltd.
  • Biocartis SA
  • Biocrates Life Sciences AG
  • Biodesix, Inc.
  • BioFire Diagnostics, LLC (Acquired by bioMérieux)
  • Biohit Oyj
  • Bioinnovation Solutions SA
  • BioMarker Strategies
  • BioMedomics, Inc.
  • bioMérieux SA
  • BioMosaics Inc.
  • BioPorto Diagnostics A/S
  • Bio-Rad Laboratories, Inc.
  • BioSystems International
  • bioTheranostics, Inc. (A bioMérieux Company)
  • Biotype Diagnostic GmbH
  • BIOUNIVERSA s.r.l.
  • Cancer Genetics, Inc.
  • Caprion, Inc.
  • CardioDx, Inc.
  • CardioGenics Holdings Inc.
  • CareDx, Inc.
  • Caris Life Sciences
  • Castle Biosciences, Inc.
  • CD Diagnostics, Inc.
  • Cellmid Ltd.
  • Centogene AG
  • Cepheid
  • Chronix Biomedical, Inc.
  • Clarient Diagnostic Services, Inc.
  • Courtagen Life Sciences, Inc.
  • Crescendo Bioscience (Subsidiary of Myriad Genetics)
  • Critical Diagnostics
  • Curetis AG
  • Cynvenio Biosystems, Inc.
  • Dako A/S (An Agilent Company)
  • Danaher Corporation
  • deCODE genetics
  • Diadexus, Inc.
  • DiaGenic ASA
  • Diagenics SE
  • Diaxonhit
  • DNA Electronics Ltd. (DNAe)
  • EntroGen, Inc.
  • Epic Sciences, Inc.
  • Epigenomics AG
  • Epinex Diagnostics, Inc.
  • Eutropics Pharmaceuticals
  • Exact Sciences Corporation
  • Exiqon A/S
  • Foundation Medicine, Inc.
  • Fujirebio Inc.
  • Fujirebio Diagnositics, Inc.
  • Gamma Therapeutics, Inc.
  • Genalyte, Inc.
  • GeneCentric Diagnostics, Inc.
  • Genection, Inc. (An Invivoscribe Company)
  • GeneNews Limited and Innovative Diagnostic Laboratory
  • GenomeDx Biosciences
  • Genomeon LLC
  • Genomic Health, Inc.
  • Genomic Vision
  • Genoptix (A Novartis Company)
  • Guardant Health, Inc.
  • HalioDx
  • Helomics Corporation
  • Hologic, Inc.
  • Illumina, Inc.
  • Immunexpress
  • Integrated Diagnostics, Inc.
  • Intrinsic LifeSciences
  • Myriad Genetics, Inc.
  • NanoString Technologies, Inc.
  • NeoGenomics, Inc./NeoGenomics Laboratories
  • Oncolab, Inc.
  • Oncospire Genomics
  • OPKO Health, Inc./OPKO Diagnostics
  • ORGENTEC Diagnostika GmbH
  • Orion Genomics
  • Ortho-Clinical Diagnostics
  • Oxford Gene Technology
  • Proteome Sciences plc
  • Psynova Neurotech Ltd.
  • Quanterix Corporation
  • Randox Laboratories Ltd.
  • Rapid Pathogen Screening, Inc.
  • ReLIA Diagnostics, Inc.
  • Roche
  • Siemens Healthcare Diagnostics
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
  • Tosoh Corporation
  • Ventana Medical Systems, Inc. (Member of the Roche Group)
  • Wako Pure Chemical Industries, Ltd.
  • XRGenomics LTD
  • ZEUS Scientific, Inc.
A broad definition of biomarkers is being used in this report. Biomarkers in this report include molecules or other characteristics that can be measured, and are indicators of a health, risk of disease, disease or other condition, prognosis, response to therapy, or other biological effect. This definition includes biomarkers that are used in drug development as surrogates, markers of drug safety, or other applications. Panels of multiple markers or analytes, which combined provide the result of one “biomarker” are also included as biomarkers in this report as analytes.

The information presented in this report is derived from publicly available information sources such as company reports and announcements, government reports and databases, medical organization reports, medical associations, and other publications. The analysis is based on the author's industry knowledge combined with literature searches and discussions with industry professionals and experts in the areas of point-of-care tests, decentralized healthcare and healthcare economics.
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times